The possibility of inoculating a third dose of Pfizer vaccine continues to be on everyone’s lips. Now, new data published by the pharmacist itself suggests that this extra puncture may push “strongly” protection against the Delta variant of the coronavirus. For this reason, announced that they could apply for an emergency use authorization for a booster injection starting in August in the United States.
The information published by the company shows that the levels of antibodies against this strain of the pathogen in people aged 18 to 55 who are immunized for the third time they are more than five times higher than after a second dose. While, in the age group 65 to 85 years, Pfizer data indicate that antibody levels against the Delta mutation are 11 times higher than after receiving a second remedy.
Awaiting review
Therefore, the Pfizer researchers emphasized that there is “an estimated potential for an increase of up to 100 times in Delta neutralization after dose three compared con the one before dose three. “ The report also indicates that antibody levels are higher after the third dose against the parent variant and Beta. But nevertheless, these data have not yet been peer reviewed or published in scientific journals.
To date, U.S. health officials have not endorsed a third vaccine for the general population, but authorities are studying the need for extra immunization in immunosuppressed people.
Increase in income
The appearance of these variants has caused Pfizer is planning to test a new version of the vaccine to specifically target Delta. The data on a hypothetical third dose coincide with the company’s announcement of a revenue forecast of about 30,000 million euros for the sale of 2,100 million doses worldwide.
–
